Mikhail Blagosklonny
Шаблон:Infobox scientist
Mikhail Blagosklonny was a scientist who studied cancer and aging. He died in October 2024. He was an adjunct faculty member at Roswell Park Comprehensive Cancer Center in Buffalo, New York.[1]
Career
Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.Шаблон:Citation needed He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center.[2]
Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[3] Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.[1]
Rapamycin and aging
Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.[5]
Editorial activities
Blagosklonny is editor-in-chief of Aging,[6] Cell Cycle,[7] and Oncotarget.[8] In addition, he is associate editor of Cancer Biology & Therapy[9] and a member of the editorial board of Cell Death & Differentiation.[10]
The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[11] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[12] in July 2015.[11] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[13]
Health
Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.[14] He died in October 2024 at the age of 63.[15]
References
- ↑ 1,0 1,1 {{{last1}}}, {{{first1}}} ({{{date}}}). "About Mikhail Blagosklonny". Roswell Park Comprehensive Cancer Center. "{{{quote}}}"
- ↑ Шаблон:Citation
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite news
- ↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial Board". {{{website}}}. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Editorial board". {{{website}}}. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "About the journal". {{{website}}}. "{{{quote}}}"
- ↑ 11,0 11,1 Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. "{{{quote}}}"
- ↑ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} (6 December 2016). "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} (26 October 2023). "My battle with cancer". {{{website}}}. "{{{quote}}}"
- ↑ {{{last1}}}, {{{first1}}} ({{{date}}}). "Passing of Dr. Misha Blagoskonny". {{{website}}}. "{{{quote}}}"
